New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2014
07:43 EDTAGIOAgios Pharmaceuticals price target raised to $51 from $38 at Leerink
Leerink raised its price target for Agios Pharmaceuticals shares to $51 saying the Phase I data presentation for the AG-221 in IDH2 mutant hematologic malignancies is coming much sooner than expected. The firm keeps an Outperform rating on the stock.
News For AGIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 26, 2015
08:23 EDTAGIOAgios Pharmaceuticals management to meet with JPMorgan
Subscribe for More Information
June 24, 2015
09:14 EDTAGIOAgios Pharmaceuticals management to meet with Leerink
Meeting to be held in Boston on June 29 hosted by Leerink.
07:32 EDTAGIOAgios Pharmaceuticals announces first patient dosed with AG-881 in Phase 1 study
Agios Pharmaceuticals announced dose administration for the first patient in a Phase 1, open-label, dose-escalation and expansion study of single agent AG-881, a small molecule that has shown in preclinical studies to fully penetrate the blood-brain barrier and inhibit isocitrate dehydrogenase-1 and IDH2 mutations in cancer models. The purpose of the Phase 1 multi-center, open-label study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-881 in advanced solid tumors. AG-881 will be administered continuously as a single agent dosed orally in a 28-day cycle. The first portion of the study includes a dose-escalation phase in which cohorts of patients will receive ascending oral doses of AG-881 to determine the maximum tolerated dose and/or the recommended Phase 2 dose based on safety and tolerability. The second portion of the study is a dose expansion phase where patients will receive AG-881 to further evaluate the safety, tolerability and clinical activity of the recommended Phase 2 dose.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use